Tislelizumab Plus Concurrent Chemoradiation in Older With ESCC - Trial NCT06061146
Access comprehensive clinical trial information for NCT06061146 through Pure Global AI's free database. This Phase 2 trial is sponsored by Tianjin Medical University Cancer Institute and Hospital and is currently Recruiting. The study focuses on Esophageal Cancer. Target enrollment is 136 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Tianjin Medical University Cancer Institute and Hospital
Timeline & Enrollment
Phase 2
Oct 05, 2023
Oct 01, 2026
Primary Outcome
PFS
Summary
This study was conducted in elderly (≥70 years old) patients with locally advanced esophageal
 squamous cell carcinoma. Aim to find the difference in efficacy and safety between
 tirilizumab combined with concurrent chemoradiation and standard concurrent chemoradiation.
 
 Concurrent chemoradiation is the standard treatment for elderly esophageal cancer.
 Tirelizumab is the first-line and second-line standard treatment for advanced esophageal
 squamous carcinoma. However, the effect of tirilizumab combined with concurrent
 chemoradiation for elder with locally advanced esophageal squamous cell carcinoma is unkown.
 
 In the study, the investigators plan to enroll 136 elderly subjects with locally advanced
 esophageal cancer from five hospitals in China. The enrolled patients will be randomly
 divided into two groups: tirilizumab combined with concurrent chemoradiation group
 (Tislelizumab + radiotherapy + tigio) and concurrent chemoradiation group (radiotherapy +
 tigio). The treatment efficiency and safety will be evaluated.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06061146
Non-Device Trial